Literature DB >> 29438961

Allele-selective RUNX1 binding regulates P1 blood group status by transcriptional control of A4GALT.

Julia S Westman1, Linn Stenfelt1, Karina Vidovic1, Mattias Möller1, Åsa Hellberg2, Sven Kjellström3,4, Martin L Olsson1,2.   

Abstract

P1 and Pk are glycosphingolipid antigens synthesized by the A4GALT-encoded α1,4-galactosyltransferase, using paragloboside and lactosylceramide as acceptor substrates, respectively. In addition to the compatibility aspects of these histo-blood group molecules, both constitute receptors for multiple microbes and toxins. Presence or absence of P1 antigen on erythrocytes determines the common P1 (P1+Pk+) and P2 (P1-Pk+weak) phenotypes. A4GALT transcript levels are higher in P1 individuals and single-nucleotide polymorphisms (SNPs) in noncoding regions of A4GALT, particularly rs5751348, correlate with P1/P2 status. Despite these recent findings, the molecular mechanism underlying these phenotypes remains elusive. The In(Lu) phenotype is caused by Krüppel-like factor 1 (KLF1) haploinsufficiency and shows decreased P1 levels on erythrocytes. We therefore hypothesized KLF1 regulates A4GALT expression. Intriguingly, P1 -specific sequences including rs5751348 revealed potential binding sites for several hematopoietic transcription factors, including KLF1. However, KLF1 binding did not explain P1 -specific shifts in electrophoretic mobility-shift assays and small interfering RNA silencing of KLF1 did not affect A4GALT transcript levels. Instead, protein pull-down experiments using P1 but not P2 oligonucleotide probes identified runt-related transcription factor 1 (RUNX1) by mass spectrometry. Furthermore, RUNX1 binds P1 alleles selectively, and knockdown of RUNX1 significantly decreased A4GALT transcription. These data indicate that RUNX1 regulates A4GALT and thereby the expression of clinically important glycosphingolipids implicated in blood group incompatibility and host-pathogen interactions.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29438961     DOI: 10.1182/blood-2017-08-803080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  The molecular genetic background leading to the formation of the human erythroid-specific Xga/CD99 blood groups.

Authors:  Chih-Chun Yeh; Ching-Jin Chang; Yuh-Ching Twu; Chen-Chung Chu; Bi-Shan Liu; Ji-Ting Huang; Shu-Ting Hung; Yung-Syu Chan; Yi-Jui Tsai; Sheng-Wei Lin; Marie Lin; Lung-Chih Yu
Journal:  Blood Adv       Date:  2018-08-14

2.  Single nucleotide polymorphisms in A4GALT spur extra products of the human Gb3/CD77 synthase and underlie the P1PK blood group system.

Authors:  Radoslaw Kaczmarek; Katarzyna Szymczak-Kulus; Anna Bereźnicka; Krzysztof Mikołajczyk; Maria Duk; Edyta Majorczyk; Anna Krop-Watorek; Elżbieta Klausa; Joanna Skowrońska; Bogumiła Michalewska; Ewa Brojer; Marcin Czerwinski
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

3.  Glycoproteomic and Phenotypic Elucidation of B4GALNT2 Expression Variants in the SID Histo-Blood Group System.

Authors:  Linn Stenfelt; Jonas Nilsson; Åsa Hellberg; Yew Wah Liew; Jenny Morrison; Göran Larson; Martin L Olsson
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

4.  Development and validation of a universal blood donor genotyping platform: a multinational prospective study.

Authors:  Nicholas S Gleadall; Barbera Veldhuisen; Jeremy Gollub; Adam S Butterworth; John Ord; Christopher J Penkett; Tiffany C Timmer; Carolin M Sauer; Nieke van der Bolt; Colin Brown; Kim Brugger; Alexander T Dilthey; Daniel Duarte; Shane Grimsley; Katja van den Hurk; John M Jongerius; Jessie Luken; Karyn Megy; Gail Miflin; Christopher S Nelson; Femmeke J Prinsze; Jennifer Sambrook; Ilenia Simeoni; Michael Sweeting; Nicole Thornton; Sara Trompeter; Salih Tuna; Ram Varma; Matthew R Walker; John Danesh; David J Roberts; Willem H Ouwehand; Kathleen E Stirrups; Augusto Rendon; Connie M Westhoff; Emanuele Di Angelantonio; C Ellen van der Schoot; William J Astle; Nicholas A Watkins; William J Lane
Journal:  Blood Adv       Date:  2020-08-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.